| Factor Information | |
|---|---|
| Data ID | 2789 |
| Factor | Predictor indications of prolonger PICU) stay: Troponine postoperative ≥4.4ng/ml |
| Description | In addition to high levels of postoperative troponine values were found to be associated to an extended PICU stay (more than seven days) by univariate analysis. Multivariate multiple logistic regression analysis revealed that, adjusting for the RACHS-1 category, the most important independent predictors of enhanced PICU stay were high preoperative NT-ProBNP (OR 5.5, 95% CI 1.2–25.5), and high levels of postoperative troponine (OR 10.5, 95% CI 2.2–49.2). |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis and risk assessment |
| Objective | To explore the value of N-terminal-pro-brain natriuretic peptide (NT-ProBNP) as a predictive biomarker of postoperative cardiovascular surgery. |
| p Value | <0.01 |
| OR | >7.0 |
| Conclusion | In addition to high levels of postoperative troponine values were found to be associated to an extended PICU stay (more than seven days) by univariate analysis. Multivariate multiple logistic regression analysis revealed that, adjusting for the RACHS-1 category, the most important independent predictors of enhanced PICU stay were high preoperative NT-ProBNP (OR 5.5, 95% CI 1.2–25.5), and high levels of postoperative troponine (OR 10.5, 95% CI 2.2–49.2). |
| Risk Factor | risk factor |
| CHD Type | |
|---|---|
| ID | 623 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | AVSD/VSD/ASD/PAPVC/TAPVC/MR/PR/AR/AP window/TGA/DORV/TOF/CoA/TA, IAA/SPS/AS/PA/PA, VSD/SV/TGA, VSD |
| Reference | |
|---|---|
| PMID | 21131684 |
| Year | 2011 |
| Title | Levels of N-terminal-pro-brain natriuretic peptide in congenital heart disease surgery and its value as a predictive biomarker |
| Sample | ||
|---|---|---|
| Population | infants, children | |
| Source | A prospective study | |
| Region | Madrid, Spain | |
| Method | a prospective observational cohort study; univariate and multivariate analasis | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | patients with CHD(Treatment) | N/A(Control) |
| Number | 68 (total) | N/A |
| Age | days to 15-years-old (median age 7 months) | N/A |
| Gender (Male: Female) | 27:41 (total) | 27:41 (total) |
| Marker Level | N/A | N/A |
